Incorporating tumour pathology information into breast cancer risk prediction algorithms

Breast Cancer Research

Table 2 Proportion of each tumour subtype in BRCA1 and BRCA2 mutation carriers and unselected controls

Tumour phenotype	Controls^a	*BRCA1*carriers	*BRCA2*carriers
TN (among ER-negative cases)	0.53	0.90	0.86
CK5/6-expressing and CK14-expressing TN^{b, c}	0.14	0.49	0.38^d
Either CK5/6-expressing or CK14-expressing TN^{b, c}	0.24	0.30	0.13^d
CK5/6-expressing TN^b (only CK5/6 tested)	0.26	0.64	0.38^d
CK14-expressing TN^b (only CK14 tested)	0.27	0.63	0.50

Data from Breast Cancer Linkage Consortium [11]. CK, cytokeratin; ER, oestrogen receptor; TN, triple negative. ^aControls were breast cancer cases unselected for family history and untested for mutation. ^bAs a proportion of all TN tumours. ^cBoth the CK5/6 status and the CK14 status have been tested. ^dAs numbers were sparse, proportions from controls were used in updating the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm.

ISSN: 1465-542X